


Patent Application No. 10/723,435  
Docket No. 01121-17272

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

|  |  |
|--|--|
| <b>ART UNIT:</b> 1615                                  | <b>AMENDMENT/RESPONSE</b>  |
| <b>EXAMINER:</b> Ghali, Isis A D                       | <b>CERTIFICATE OF MAILING<br/>UNDER 37 C.F.R. § 1.8</b>  |
| <b>APPLICANT:</b> Weihong Xiong et al.                 | <b>DATE OF DEPOSIT:</b> <u>2-12-07</u>   |
| <b>SERIAL NO.:</b> 10/723,435                          | I hereby certify that this paper or fee (along with any paper or fee referred to as being attached or enclosed) is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. |
| <b>FILED:</b> 11/26/03                                 | <br>Katherine C. Johnson   |
| <b>CONFRM. NO.:</b> 6215                               |  |
| <b>DOCKET NO.:</b> 01121-T8341.NP.CON                  |  |
| <b>FOR:</b> TRANSDERMAL ADMINISTRATION OF<br>HUPERZINE |  |

**AMENDMENT AND RESPONSE UNDER 37 C.F.R. § 1.111 AND  
STATEMENT OF SUBSTANCE OF INTERVIEW UNDER 37 C.F.R. § 1.133**

THORPE NORTH & WESTERN, LLP  
8180 South 700 East, Suite 350  
Sandy, Utah 84070

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In response to the communication mailed September 11, 2006, please enter this Interview Summary Statement and this Amendment, and reconsider this application in view of the accompanying responsive remarks. A petition for a two month extension of time and the appropriate fee is enclosed herewith.

### **INTRODUCTORY COMMENTS FOR AMENDMENTS**

Please amend the claims in the manner indicated below. In the following amendments, an underline is used to indicate added text, and strikeouts are used to indicate deleted text. Brackets may also be used for deleted text or characters when strikeouts are not sufficiently clear, e.g., such as striking out a hyphen. Claims 81, 87, 90, and 94 have been amended. Claim 81 has been amended to recite permeation enhancers and transdermal patch compositions. Specific support is found on page 7, lines 8-13; page 23, lines 15-19; 20-23 (Azone exclusion); page 24, lines 1-6 (Azone exclusion); page 33, lines 2, 20-24; page 35, line 24; and page 36, line 1. Claim 87 has been rewritten in independent form and amended to include the elements of the claims from which it previously depended, namely former claim 81. Claim 90 has been amended in a like manner. Claim 94 has been amended to clarify the method of coadministration, as the Examiner found the claim ambiguous. Claims 98-102 have been added reciting various embodiments of the present invention relating to permeation enhancers and transdermal patches. Specifically, support is found on page 24, lines 7-16, 18; page 25, lines 3, 16, 20; and page 33, lines 15-19. As such, no new matter has been added.